Stemline Therapeutics Inc Gets a Buy Rating from Jefferies

By Austin Angelo

In a report released yesterday, Eun Yang from Jefferies reiterated a Buy rating on Stemline Therapeutics Inc (NASDAQ: STML), with a price target of $16. The company’s shares closed yesterday at $8.25.

According to, Yang is a 4-star analyst with an average return of 2.9% and a 48.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Achillion Pharmaceuticals, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Stemline Therapeutics Inc is Strong Buy and the average price target is $25.50, representing a 209.1% upside.

In a report issued on May 12, Cowen & Co. also reiterated a Buy rating on the stock.

The company has a one year high of $14.60 and a one year low of $5.50. Currently, Stemline Therapeutics Inc has an average volume of 231.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. It develops a discovery platform called StemScreen, which identifies novel compounds that target and kill cancer stem cells. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.